• All Share : 51568.13
    UP 1.20%
    Top40 - (Tradeable) : 46217.44
    UP 1.20%
    Financial 15 : 16370.13
    UP 1.21%
    Industrial 25 : 69014.95
    UP 1.27%
    Resource 10 : 33046.02
    UP 1.29%

  • ZAR/USD : 13.5526
    DOWN -1.43%
    ZAR/GBP : 20.5725
    DOWN -1.43%
    ZAR/EUR : 15.2856
    DOWN -1.01%
    ZAR/JPY : 0.1122
    DOWN -1.75%
    ZAR/AUD : 9.6246
    DOWN -0.87%

  • Gold US$/oz : 1133.5
    DOWN -0.32%
    Platinum US$/oz : 912.19
    UP 0.17%
    Silver US$/oz : 15.32
    UP 0.39%
    Palladium US$/oz : 708.8
    UP 1.54%
    Brent Crude : 48.73
    UP 1.25%

  • All data is delayed by 15 min. Data supplied by Profile Data
    Hover cursor over this ticker to pause.

Mon Oct 05 12:12:28 SAST 2015

Council withdraws diabetes medicine

HARRIET MCLEA | 06 July, 2011 23:45
A doctor holding a stethoscope.

The Medicines Control Council has withdrawn the diabetes medicine Avandia from the market because it contains a substance that might increase the likelihood of a heart attack.

The medication, produced by GlaxoSmithKline, is prescribed to some type2 diabetics.

The council made the decision five weeks ago "due to safety risks" attributed to rosiglitazone, a constituent of Avandia.

A statement by the council on Tuesday said: "Rosiglitazone is associated with an increased risk [of] heart failure, myocardial infarction [heart attack] and cardiac arrest".

Avandia was registered in South Africa in October 2004. The EU and the UK have already withdrawn rosiglitazone-containing medicine from their markets.

Spokesman for the department of health Fidel Hadebe could not say how many South Africans take Avandia.

"Given the reality that diabetes is a huge problem in South Africa, it is obvious that quite a number of people are on [Avandia]," he said.

Diabetes nurse educator Razana Allie, of Diabetes SA, said Metformin was one of a few alternative products that could be used in South Africa.

The local representatives of GlaxoSmithKline could not be reached for comment.


If you have an opinion you would like to share on this article, please send us an e-mail to the Times LIVE iLIVE team. In the mean time, click here to view the Times LIVE iLIVE section.